Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer.

about

Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer.

Item

http://www.wikidata.org/entity/Q52591096

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer.

@en

Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer.

@nl

type

Item

label

Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer.

@en

Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer.

@nl

prefLabel

Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer.

@en

Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer.

@nl

P1476

Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer.

@en

P2093

Beth Eaby-Sandy

http://www.w3.org/2001/XMLSchema#string

Corey J Langer

http://www.w3.org/2001/XMLSchema#string

Jennifer Choi

http://www.w3.org/2001/XMLSchema#string

Mario E Lacouture

http://www.w3.org/2001/XMLSchema#string

P2860

Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK

Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR)

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

P304

891-899

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2017-0582

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Chia-Yu Chu

P577

2018-04-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29650685

http://www.w3.org/2001/XMLSchema#string

P932

6156184

http://www.w3.org/2001/XMLSchema#string